

Services That Require Precertification

Standard Precertification List Effective: January 1, 2023

This applies to elective, nonemergency services.

Some services or supplies in this list may not be covered by your benefits plan. Please check your benefit plan documents.

Inpatient services

- Acute rehabilitation admissions
- Elective surgical and nonsurgical inpatient admissions
- Elective inpatient hospital-to-hospital transfers
- Inpatient hospice admissions
- Long term acute care (LTAC) facility admissions
- Skilled nursing facility admissions

Procedures

- Carticel (ACI), osteochondral allograft, and autograft transplantations
- Cochlear implant surgery
- Obesity surgery

Reconstructive procedures and potentially cosmetic procedures

- Blepharoplasty/blepharoptosis repair
- Bone graft, genioplasty, and mentoplasty
- Breast: reconstruction, reduction, augmentation, mammoplasty, mastopexy, insertion and removal of breast implants
- Canthopexy/canthoplasty
- Cervicoplasty
- Chemical peels
- Dermabrasion
- Excision of subcutaneous skin and/or subcutaneous tissue
- Gender reassignment surgery
- Genetically and bioengineered skin substitutes for wound care
- Hair transplants
- Injectable dermal fillers
- Keloid removal
- Lipectomy, liposuction, or any other excess fat removal procedure
- Otoplasty
- Rhinoplasty
- Rhytidectomy
- Scar revision
- Skin closures including:
 - Skin grafts
 - Skin flaps
 - Tissue grafts
- Surgery for varicose veins, including perforators and sclerotherapy

Experimental or investigational

- Any procedure, device, or service that may be considered experimental or investigational including:
 - New emerging technology/procedures, as well as existing technology and procedures applied for new uses and treatments

Day rehabilitation programs

Elective (nonemergency) ground, air, and sea ambulance transportation

Outpatient private-duty nursing

Interventional pain management services

- Epidural injection procedures and diagnostic selective nerve root blocks
- Paravertebral facet injection/nerve block/ neurolysis
- Regional sympathetic nerve block
- Sacroiliac joint injections
- Implanted spinal cord stimulators

Radiology

- Cardiac blood pool imaging or MUGA-resting or exercise
- Computed tomography (CT), cardiac
- Computed tomography (CT), coronaries
- Computed tomography angiogram (CTA), coronaries
- Magnetic resonance angiography (MRA), cardiac
- Magnetic resonance imaging (MRI), cardiac
- Myocardial perfusion imaging
- Positron emission tomography (PET) scan/ positron emission transverse tomography (PETT) scan
- Single photon emission computerized tomography (SPECT), technetium or thallium

Home-Care Services

- Enteral feeding therapy (tube feeding)
- Home health care
- Home infusion therapy
- Hospice

Prosthetics/orthoses

- Custom ankle-foot orthoses
- Custom knee-ankle-foot orthoses
- Custom knee braces
- Custom limb prosthetics including accessories/ components
- Repair or replacement of all prosthetics/orthoses that require precertification

Durable medical equipment (DME)

- Bone growth stimulators
- Bone-anchored (osseointegrated) hearing aids
- Continuous positive airway pressure (CPAP) device and bi-level (Bi-PAP) devices
- Dynamic adjustable and static progressive stretching devices (excludes CPMs)
- Electric, power, and motorized wheelchairs including custom accessories
- Insulin pumps
- Manual wheelchairs unless they are rented
- Negative pressure wound therapy
- Neuromuscular stimulators
- Power operated vehicles (POV)

- Pressure reducing support surfaces including:
 - Air fluidized bed
 - Non-powered advanced pressure reducing mattress
 - Powered air flotation bed (low air loss therapy)
 - Powered pressure reducing mattress
- Push rim activated power assist devices
- Repair or replacement of all DME items that require precertification
- Speech generating devices

Medical foods

Hyperbaric oxygen therapy

Proton beam therapy

Sleep studies (facility based)

Transplants

- All transplant procedures, with the exception of corneal transplants

Mental health/serious mental illness/substance use disorder

Precertification review for this service is provided by Magellan Healthcare, Inc., an independent company.

- Mental health and serious mental illness treatment (inpatient/partial hospitalization programs/intensive outpatient programs)
- Repetitive transcranial magnetic stimulation (rTMS)
- Substance use disorder treatment (inpatient/partial hospitalization programs/intensive outpatient programs)

Autism spectrum disorders

- Applied behavioral analysis

Genetic and Genomic Tests Requiring Precertification

The following list is a guide to the types of genetic and genomic tests that require precertification. Due to the volume of tests, it is not possible to list each test separately.

Hereditary cancer syndromes

- BRCA gene testing (breast and ovarian cancer syndrome)
- Lynch syndrome gene testing
- Familial adenomatous polyposis gene testing
- PTEN gene testing (Cowden syndrome)
- General cancer type panels (such as colon, breast, or neuroendocrine cancers)

Hereditary heart diseases

- Long QT syndrome gene testing
- Aortic dilation or aneurysm syndrome testing (includes Marfan syndrome)

Other full gene analysis testing

- Cystic fibrosis full gene sequencing and deletion/duplication analysis
- PMP22 full gene sequencing and deletion/ duplication analysis (Charcot- Marie-Tooth, hereditary neuropathy)

Tests for many genetic disorders simultaneously

- Expanded carrier screening panels (such as Carrier Status DNA Insight®, Counsyl Family Prep Screen, Pan-Ethnic Carrier Screening)
- Hearing loss panels
- Intellectual disability panels
- Noonan spectrum disorders panels

Specialty oncology tests

- Cancer gene expression or protein signature tests (such as OncotypeDX®, MammaPrint®, Afirma®, Prosigna®, HeproDX™)
- Tumor molecular profiling (such as FoundationOne®, neoTYPE™, OncoPlexDx®, and many others)
- Tissue of origin testing (for cancer of unknown primary)
- PCA3 testing for prostate cancer

Pharmacogenomic tests

- Cytochrome P450 metabolism gene testing (CYP2D6, CYP2C9, CYP2C19)
- Specialized drug response gene panels (such as Assurex GeneSight®, GeneTrait, Genecept®, Millennium PGTSM)
- Warfarin response testing
- MGMT methylation analysis for glioblastoma

Other specialty tests

- Coronary artery disease risk testing (such as CorusCAD®, CardioIQ®, APOE, ACE, KIF6)
- Heart disease risk testing (such as CorusCAD®, CardioIQ®, APOE, ACE, KIF6, MTHFR)

Genome-wide tests

- Microarray studies
- Whole exome testing
- Whole genome testing
- Mitochondrial genome or nuclear testing

ANY genetic test for more than one gene or condition (often includes words like “panel” or “comprehensive” in the name)

ANY genetic test that will be billed with a non-specific procedure code

- Billed with CPT® codes 81400–81408 (CPT Copyright 2016 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.)
- Billed with an unlisted code: 81479, 81599, 84999

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

* Pending FDA approval.

** All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.

Specialty Drugs that Require Precertification

All listed brands and their generic equivalents or biosimilars require precertification. This list is subject to change.

Amyotrophic Lateral Sclerosis agents

- Radicava™ (ravulizumab)
- tofersen*

Antineoplastic agents/Chemotherapy

- Abraxane® (paclitaxel protein-bound particles)
- Adcetris® (brentuximab vedotin)
- Alimta® (pemetrexed disodium)
- Alymsys® (bevacizumab) (except for ophthalmological conditions)
- Avastin®‡ (bevacizumab) (except for ophthalmological conditions)
- Azedra® (iobenguane I- 131) e-zzxf)
- Blenrep™ (belantamab mafodotin)
- Blincyto® (blinatumomab)
- Cyramza® (ramucirumab)
- Darzalex® (daratumumab)
- Darzalex Faspro™ (daratumumab/hyaluronidase-fihj)
- Enhertu (fam-trastuzumab-deruxtecan- nxki)
- Erbitux® (cetuximab)
- Herzuma® (trastuzumab-pkrb)
- Herceptin Hylecta™ Trastuzumab
- Instiladrin® (nadofaragene firadenovec)
- Kadcyła® (ado-trastuzumab emtansinel)
- Kanjinti™ (trastuzumab-anns)
- Kimmtrak® (tebentafusp-tebn)
- Kyprolis® (carfilzomib)
- Lumoxiti™ (moxetumomab pasudotox-tdfk)
- Margenza™ (margetuximab)
- mirvetuximab
- Monjuvi® (tafasitamab-cxix)
- mosunetuzumab*
- Mvasi™ (bevacizumab- awwb) (except for ophthalmological conditions)
- Ogivri™ (trastuzumab-dkst)
- Ontruzant® (trastuzumab-dttb)
- Opdualag™ (nivolumab andrelatlimab-rmbw)
- oportuzumab monatox **
- Padcev™
- Pemfexy™ (pemetrexed)
- Perjeta® (pertuzumab)
- Phesgo™ (pertuzumab/trastuzumab/hyaluronidas e-zzxf)
- Polivy™ Polatuzumab vedotin-piiq
- Poteligeo™ (mogamulizumab)
- Provenge® (sipuleucel-T)
- Riabni™ (rituximab-arrx)
- Rituxan®‡ (rituximab)

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

* Pending FDA approval.

** All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.

- Rituxan Hycela™ (rituximab/hyaluronidase human)
- Ruxience™ Rituximab-pvvr
- Rybrevant (amivantamab-vmjw)
- Rylaze™ (asparaginase *Erwinia chrysanthemi* [recombinant]-rywn)
- Sarclisa® (isatuximab-irfc)
- SH-111*
- Taclanits* (paclitaxel injection concentrate for suspension)
- teclistamab*
- Tivdak™ (tisotumab vedotin-tftv)
- Trazimera™ (trastuzumab-qyyp)
- tremelimumab*
- Trodelvy™ (Sacituzumab govitecan-hziy)
- Truxima® (rituximab-abbs)
- Vegzelma® (bevacizumab-adcd) (except for ophthalmological conditions)
- Xofigo (radium Ra 223)
- Yervoy™ (ipilimumab)
- Zepzelca™ (lurbinectedin)
- Zevalin® (ibritumomab tiuxetan)
- Zirabev® (except for ophthalmological conditions)
- Zynlonta™ (loncastuximab tesirine)

Anti-PD-1/ PD-L1 human monoclonal antibodies/Chemotherapy**

- balstilimab*
- Bavencio® (avelumab)
- Imfinzi™ (durvalumab)
- Jemperli (dostarlimab-gxly)
- Keytruda™ (pembrolizumab)
- Libtayo® (cemiplimab-rwlc)
- Opdivo® (nivolumab)
- penpulimab*
- retifanlimab*
- sintilimab*
- Tecentriq™ (atezolizumab)
- tislelizumab*
- toripalimab*

Bone-modifying agents

- Evenity® (romosozumab-aqqg)
- Prolia® (denosumab)
- Xgeva® (denosumab)

Botulinum toxin agents

- Botox® (onabotulinumtoxinA)

Chemotherapy-induced nausea and vomiting (CINV) agents

- Sustol® (granisetron extended-release for injection)

Chimeric antigen receptor (CAR-T) therapies/Chemotherapy**

- Abecma™ (idecabtagene vicleucel)

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

* Pending FDA approval.

** All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.

- Breyanzi® (lisocabtagene maraleucel)
- Carvykti™ (ciltacabtagene autoleucel)
- Kymriah™ (tisagenlecleucel)
- Tecartus™ (brexucabtagene autoleucel)
- Yescarta™ (axicabtagene ciloleucel)

Endocrine/metabolic agents

- Acthar H.P.® (corticotropin)
- cosyntropin depot*
- Lutathera® (lutetium Lu 177 dotatate) /**chemotherapy**
- Makena® (hydroxyprogesterone caproate)
- Sandostatin LAR (octreotide) /**chemotherapy**
- Somatuline depot (lanreotide) /**chemotherapy**

Enzyme replacement agents**

- Aldurazyme® (laronidase)
- Brineura™ (cerliponase alfa)
- Cerezyme® (imiglucerase)
- cipaglucosidase alfa*
- Elaprase® (idursulfase)
- Elelyso® (taliglucerase alfa)
- Fabrazyme® (agalsidase beta)
- Kanuma® (sebelipase alfa)
- Lumizyme® (alglucosidase alfa)
- Mepsevii™ (vestronidase alfa-vjbc)
- Naglazyme® (galsulfase)
- Nexviazyme® (avalglucosidase alfa)
- pegunigalsidase alfa*
- Replagal®* (agalsidase alfa)
- Revcovi™ (elapegademase-lvlr)
- Vimizim™ (elosulfase alfa)
- VPRIV® (velaglucerase alfa)
- Xenpozyme® (olipudase alfa)

Gene Replacement/Gene Editing therapy**

- beremagene geperpavec*
- etranacogene dezaparvovec*
- Luxturna™ (voretigene neparvovec-rzyl)
- Roctavian* (valoctocogene roxaparvovec)
- Skysona™ (elivaldogene autotemcel)
- Zolgensma® (onasemnogene abeparvovec-xioi)
- Zynteglo® (betibeglogene autotemcel)

Hemophilia/Coagulation factors **

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

* Pending FDA approval.

** All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.

Hyaluronate acid products

- Cingal* (triamcinolone and Monovisc)
- Durolane®
- Euflexxa™
- Gel-One®
- Gelsyn-3™
- GenVisc 850®
- Hyalgan®
- Hymovis®
- Supartz®
- Synojoynt™
- Triluron™
- TriVisc™
- VISCO-3®

Immunological agents

- Actemra® IV (tocilizumab)
- Avsola™ (infliximab-axxq)
- Benlysta® IV (belimumab)
- Entyvio™ (vedolizumab)
- Ilumya™ (infliximab-dyyb)
- Inflectra™ (tildrakizumab- asmn)
- Infliximab (unbranded)
- Ixifi™ (infliximab-qbtx)
- Orencia® IV (abatacept)
- Remicade®‡ (infliximab)
- Renflexis™ (infliximab- abda)
- Saphnelo™(anifrolumab)
- Simponi® Aria (golimumab for infusion)
- Skyrizi ® IV*(risankizumab-rzaa)
- Spevigo® (spesolimab)
- Stelara® IV (ustekinumab)

Intravenous Immune Globulin/ Subcutaneous Immune Globulin (IVIG/SCIG)**

Multiple sclerosis agents **

- Lemtrada® (alemtuzumab)
- Ocrevus™ (ocrelizumab)
- Tysabri® (natalizumab)
- ublituximab*

Neutropenia

- efbemalenograstim *
- Fulphila™ (pegfilgrastim- jmbd)
- Fylnetra® (pegfilgrastim-pbbk)
- Lapelga*
- Neulasta®‡ (pegfilgrastim)
- Neulasta Onpro™ (pegfilgrastim body injector kit)
- Neupogen® (filgrastim)

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

* Pending FDA approval.

** All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.

- Nivestym™ (filgrastim-aafi)
- Nyvepria™ (pegfilgrastim-apgf)
- plinabulin*
- Releuko™ (filgrastim-ayow)
- Rolvedon™ (eflapegrastim)
- Stimufend® (pegfilgrastim-fpgk)
- Udenyca™ (pegfilgrastim-cbqv)
- Ziextenzo® (pegfilgrastim-bmez)

Ophthalmic agents

- abicipar*
- Beovu (brolucizumab-dblI)
- Byooviz™ (ranibizumab-nuna)
- Cimerli™ (ranibizumab-eqrn)
- Eylea® (aflibercept)‡
- Lucentis®
- Susvimo™ (ranibizumab injection, port delivery system)
- Tepezza™ (teprotumumab-trbw)
- Vabysmo® (faricimab-svoa)

Pulmonary arterial hypertension**

- Flolan® (epoprostenol GM)
- Remodulin® (treprostinil)
- Revatio® (sildenafil)
- Trevyent* (treprostinil)
- Tyvaso® (treprostinil)
- Veletri® (epoprostenol AS)
- Ventavis® (iloprost)

Respiratory agents

- Cinqair® (reslizumab)
- Synagis® (respiratory syncytial virus [RSV], monoclonal antibody, recombinant)
- Tezspire™ (tezepelumab-ekko)
- Xolair® (omalizumab)

Respiratory enzymes (Alpha-1 antitrypsin)**

- Aralast
- Glassia™
- Prolastin®
- Zemaira®

Miscellaneous therapeutic agents

- Adakveo® (crizanlizumab-tmca)
- Ampligen®* (rintatolimod)
- Amvuttra™ (vutrisiran)
- Cosela® (trilaciclib)
- Crysvita•(burosumab-twza)
- donislecel*
- Enjaymo (sutimlimab-jome)

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

* Pending FDA approval.

** All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.

- Evkeeza™ (evinacumab)
- Exenatide sustained- release ITCA 650*
- Gamifant® (emapalumab-lzsg)
- Givlaari® (givosiran)
- Ilaris® (canakinumab)
- Krystexxa® (pegloticase)
- Leqvio® (inclisiran)
- narsoplimab*
- Onpattro™ (patisiran)
- Oxlumo® (lumansiran)
- Reblozyl (luspatercept-aamt)
- Remune*
- Rethymic™ (allogeneic processed thymus tissue-agdc)
- Soliris®‡ (eculizumab)
- Spinraza™ (nusinersen)
- teplizumab*
- Ultomiris™ (ravulizumab-cwvz)
- Uplizna™ (inebilizumab)
- Vyepiti™ (eptinezumab-jjmr)
- Vyvgart™ (efgartigimod alfa-fcab)
- Xiaflex®

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

* Pending FDA approval.

** All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.